Comparison
Noopept vs BPC-157
Noopept
Russian-developed proline-containing dipeptide ~1000x more potent than piracetam by weight. Often grouped with racetams.
BPC-157
Pentadecapeptide from gastric juice. Used (research) for soft-tissue healing. Not approved for human use.
| Field | Noopept | BPC-157 |
|---|---|---|
| Category | peptide | peptide |
| Dose range | 10–30mg | 0.2–0.5mg |
| Half-life | 0.5h | — |
| Onset | 20min | — |
| Evidence | EVIDENCEB | EVIDENCEC |
| Safety | ●●●●○ | ●●○○○ |
| Legal (US) | USUnscheduled | USResearch chemical |
| PubMed refs | 90 | 110 |
The comparison in plain English
Auto-generated from dataNoopept and BPC-157 are both in the peptide category respectively. Noopept Russian-developed proline-containing dipeptide ~1000x more potent than piracetam by weight. BPC-157 Pentadecapeptide from gastric juice.
Bottom line
Noopept (evidence B, safety 4/5) has a weaker evidence base than BPC-157 (evidence C, safety 2/5). Noopept has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose Noopept if
Noopept is the better fit when your goal aligns with its mechanism (Increases BDNF and NGF expression in the hippocampus and prefrontal cortex) and the dose range (10–30mg) suits your protocol. Half-life is 0.5h.
Choose BPC-157 if
BPC-157 is the better fit when your goal aligns with its mechanism (Stimulates angiogenesis (new blood vessel formation) at injury sites, modulates nitric oxide and growth hormone receptor signalling, and increases collagen production in fibroblasts) and the dose range (0.2–0.5mg) suits your protocol. Half-life is —h.